Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
475.6 USD | +0.41% | -1.60% | +16.45% |
17/06 | Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465 | MT |
14/06 | Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.45% | 122B | |
+19.15% | 113B | |
+2.62% | 22.66B | |
-16.26% | 21.34B | |
-39.57% | 16.92B | |
-13.99% | 16.68B | |
-16.29% | 16.61B | |
+3.15% | 13.62B | |
+21.93% | 11.04B | |
+109.17% | 10.43B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing